Global Conference 2015

DNA sequencing technology has advanced at an extraordinary pace since the Human Genome Project was completed in 2003. That first mapping of the genome took 13 years and cost $3 billion. Today, a human genome can be sequenced in less than three days at a cost of approximately $1,000. As a result, DNA sequencing is shifting from a tool used for scientific research to a key technology used in clinical medicine, including the diagnosis and treatment of cancer. The company most responsible for driving this revolution in DNA sequencing technology is San Diego-based Illumina, whose revenue has grown from $367 million in 2007 to $1.8 billion in 2014 as demand for its products has exploded. In this panel, Ron Baron, founder and CIO of Baron Capital, will interview Jay Flatley, CEO of Illumina. Their discussion will provide members of the audience with a better understanding of Illumina's business, market opportunity and competitive advantages. They also will learn more about the promise of genomics and how it can improve human health.

Introduction By

Sarah Sandler

Director, Business and Program Development, Milken Institute


Ron Baron

Founder, CEO and Chief Investment Officer, Baron Capital Group


Jay Flatley

CEO, Illumina

Return to Program Detail